Cytovale
SAN FRANCISCO, CA · Biotechnology, Other · 120 employees
Cytovale is a medical diagnostics company focused on providing a more rapid and insightful way to diagnose fast-moving and immune-mediated diseases. Our FDA cleared IntelliSep test is pioneering a new way of quickly and accurately analyzing white blood cells to stratify a patient’s risk of sepsis by performing a biomechanical evaluation of white blood cells collected from a standard blood draw in
Funding history
- Series D — $100.0M — Oct 2024
- Series C — $84.0M — Nov 2023
- Venture - Series Unknown — $16.4M — Jan 2022
- Venture - Series Unknown — $8.0M — Jan 2021
- Venture - Series Unknown — $7.4M — Oct 2019
Recent signals
- Apr 07, 2026: Cytovale Appoints Eric Khairy as Chief Marketing Officer
- Oct 10, 2024: Raised $100.0M in Series D
- Mar 04, 2024: Cytovale Appoints Christopher Slachta as Chief Operating Officer
- Nov 15, 2023: Raised $84.0M in Series C
- Jan 03, 2022: Raised $16.4M in Venture - Series Unknown
- Jan 04, 2021: Raised $8.0M in Venture - Series Unknown
- Oct 30, 2019: Raised $7.4M in Venture - Series Unknown
- Dec 26, 2017: Raised $7.2M in Venture - Series Unknown
See plans & pricing → Track Cytovale’s funding, hiring, and signals — with verified contacts — on Fundz.